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ABSTRACT (Maximum 200 Words)
The objective of this project was to determine whether hyaluronan interactions are involved in growth and invasion of tumor cells, especially mammary carcinoma. Our working hypothesis is that polymeric hyaluronan interacts in a multivalent manner with cell surface receptors such as CD44, thus inducing clustering of these receptors and concomitant intracellular signaling that leads to altered cell behavior typical of tumor cells. To test this hypothesis, two means of perturbing hyaluronan-protein interactions in vitro and in vivo have been employed in our studies. First, cDNA transfection and recombinant adenovirus infection have been used to overexpress soluble hyaluronan-binding proteins in tumor cells; these proteins would be expected to act as a sink that competes for binding of endogenous hyaluronan. Second, tumor cells have been treated with hyaluronan oligomers; the oligomers compete for multivalent binding of endogenous polymeric hyaluronan by binding to receptors monovalently. Our results have shown that such perturbations of hyaluronan interactions inhibit tumor cell growth in vivo, anchorage-independent growth in soft agar, and invasion through extracellular matrix in vitro. The results of these studies provide strong evidence for the direct involvement of hyaluronan-tumor cell interactions in regulation of tumor growth and invasion. 14 
INTRODUCTION:
Many studies have implied that hyaluronan interactions at the surface of tumor cells may be a necessary part of the cascade of events leading to tumor progression. The objective of this project is to determine whether these hyaluronan interactions are involved in growth and invasion of tumor cells, especially mammary carcinoma, and if so to begin studies of the underlying mechanisms whereby hyaluronan has its effects. Our working hypothesis, based on previous work, is that polymeric hyaluronan interacts in a multivalent manner with cell surface receptors such as CD44 (1) , thus inducing clustering of these receptors and concomitant intracellular signaling that leads to altered cell behavior typical of tumor cells (2, 3) . We reason that perturbation of endogenous hyaluronan binding reactions will lead to reversal of this altered cell behavior. Two means of perturbing hyaluronan-protein interactions in vitro and in vivo have been employed in our studies. First, cDNA transfection and recombinant adenovirus infection have been used to over-express soluble hyaluronan-binding proteins in tumor cells; these proteins would be expected to act as a sink that competes for binding of endogenous hyaluronan. Second, tumor cells have been treated with hyaluronan oligomers; the oligomers compete for multivalent binding of endogenous polymeric hyaluronan by binding monovalently to receptors (1) ; since polymeric hyaluronan is necessary for clustering of cell surface receptors, replacement with oligomers would reverse this clustering and consequent signaling events. Thus it is expected that both of these approaches would inhibit hyaluronan-induced changes associated with tumorigenesis.
From September 1, 1996, to June 30, 1999, Ms Rebecca Peterson examined the effects of over-expression of soluble CD44 on ascites growth in vivo and anchorage-independent growth in vitro, using murine mammary carcinoma cells. From A(i). Over-expression of soluble CD44 inhibits growth of TA3/St murine mammary carcinoma cells in ascites. Hyaluronan accumulates in ascites during intraperitoneal proliferation of TA3/St murine mammary carcinoma cells and at sites of their invasion of the peritoneal wall (4). To determine whether hyaluronan is functionally involved in these events, mice were injected intraperitoneally with stable transfectants of TA3/St cells that overexpress soluble CD44, a hyaluronan-binding protein that would be expected to compete with endogenous hyaluronan-protein interactions. The behavior of these transfectants was compared with that of transfectants expressing mutated soluble CD44 that does not bind hyaluronan. The soluble CD44 transfectants temporarily grew at a reduced rate within the peritoneal cavity, then went into G1 arrest and were subsequently cleared from the peritoneum. However, the transfectants overexpressing mutant soluble CD44 that does not bind hyaluronan exhibited similar ascites accumulation, growth rates and cell cycle profiles in vivo to that of wild type and vector-transfected TA3/St cells, both of which continued to grow until the tumors became fatal. The soluble CD44-transfected TA3/St cells also failed to attach to and form tumors in the peritoneal wall. These experiments indicate that perturbation of hyaluronan interactions by soluble CD44 alters the growth characteristics of the tumor cells, either directly or indirectly, and leads to inhibition of ascites growth and invasion in vivo. A(ii). Soluble CD44-transfected TA3/St mammary carcinoma cells have lost the capacity for anchorage-independent growth in vitro. It was not clear from the in vivo results obtained in the above study whether overexpression of soluble CD44 has a direct effect on tumor cell growth or whether its effect was an indirect consequence of another event in vivo. Thus additional evidence was sought to discriminate between these two possible explanations. First, proliferation of the soluble CD44 transfectants and control cells was compared in monolayer culture in tissue culture wells. Each cell line grew at approximately the same rate over a five day period and all cell lines exhibited similar cell cycle profiles. This result was in contrast to the differences observed previously between the growth of soluble CD44 transfectants in ascites vs that of controls in ascites, where the former were found to go into G1 arrest. Anchorage independent growth of the various cell lines in soft agar was then examined. Dramatic differences in size and number of colonies formed between the soluble CD44 transfectants and control cells were observed. The wild type, vector-transfected cells and mutant soluble CD44-transfected cells formed many times more colonies than the soluble CD44 transfectants, and the colonies formed by the control cells were much larger than those few colonies formed by the soluble CD44 transfectants. These results demonstrate that the soluble CD44 transfectants, but not the mutant soluble CD44 transfectant, have lost their ability to exhibit anchorage independent growth in soft agar, one of the most reliable indicators for the transformed state of cells (5) . We conclude that endogenous hyaluronan produced by the tumor cells themselves directly serves an important function in anchorage independent growth, and that hyaluronan interactions at the cell surface are, at least under some circumstances, crucial to mammary cancer cell growth characteristics in vitro and in vivo. Task 1 is almost complete and is reported in section B(i) below. Our work to date on Task 2 is almost complete and is reported in section B(ii) below. The in vivo work for Task 3 has not been possible to complete in the time frame of the award. However, considerable progress has been made demonstrating inhibition of tumor cell growth and invasion in vitro by two recombinant adenoviruses expressing two different soluble hyaluronan-binding proteins; this is reported in section B(iii) below. Additional work showing that hyaluronan oligomers also inhibit tumor cell growth and invasion is also reported in B(iii). These results provide a strong basis for future experiments in vivo. B(i). Human cancer cells synthesize soluble CD44 mRNA de novo. CD44 is usually expressed as a cell surface glycoprotein that, in many cell types, is present as numerous isoforms due to alternative splicing. Membrane-bound isoforms of CD44 contain common cytoplasmic, transmembrane and N-terminal hyaluronan-binding domains, but variable exon products are spliced into a single site in the membrane-proximal portion of the extracellular domain. Soluble forms of CD44 are present in the circulation and their levels are elevated in the sera of many tumor patients (6, 7) . The latter observation, together with the finding that over-expression of soluble CD44 protein inhibits growth of several tumor types in vivo, has led to the suggestion that soluble CD44 may act as an antagonist of membrane CD44. Cell culture studies by other laboratories suggest that soluble CD44 can be generated, at least in part, by proteolytic cleavage of membrane-bound CD44 (7) . Our lab has shown in previous work that soluble CD44 is produced in embryonic murine tissues by alternative splicing, thus providing a mechanism of production de novo that is subject to rigorous cellular control (8) . These murine soluble CD44 isoforms arise by alternative splicing of a newly discovered exon that lies between the previously described variant exons v9 and v10; this additional exon includes a stop codon (8) . Some murine soluble CD44 isoforms contain an additional novel domain arising from a 3' extension of exon v9, termed v9b (8) . Thus, truncated CD44 isoforms lacking transmembrane and cytoplasmic domains are synthesized then secreted rather than inserted into the plasma membrane.
We have now shown that various types of human tumor cells also produce soluble isoforms of CD44 by alternative splicing of novel exonic sequences between the previously described v9 and vi0 exons. However, the new sequences are quite different from those in the mouse. The human sequences occur as a 3' extension of v9 and a 5' extension of vl0. The extension of human v9 includes a region homologous to murine v9b and a new exonic region, v9c, the homologue of which is present within an intron in the mouse. The 5' extension of human vlO is also intronic in the mouse. Despite the differences in arrangement of the mouse and human CD44 genes described above, the new exonic sequences between v9 and vlO give rise to stop codons that would lead to secreted isoforms of CD44 in both species. Since the alternative splicing that gives rise to soluble CD44 isoforms occurs 3' of v9 in both species, many variant isoforms of soluble CD44 can be produced using exons v2-v9 in the human and vl-v9 in the mouse. We have characterized transcripts for several different variant isoforms of soluble CD44 both in the mouse embryo and in human tumor cells. We have shown translation of secreted, soluble forms of CD44 from such transcripts in mouse cells but not yet in human. The physiological role of these secreted CD44 isoforms is not yet established but it is possible that they may act as antagonists or modulators of membrane-bound CD44 function (7, 9) . Indeed, recent studies in our laboratory show that overexpression of soluble CD44 isoforms in murine tumor cells inhibits tumor growth (section A above, and Appendix) and metastasis (2) in vivo, highlighting the potential importance of soluble isoforms of CD44 in regulation of membrane-bound CD44 activity. B(ii). Construction of recombinant adenoviruses driving expression of soluble hyaluronan-binding proteins. For efficient expression of hyaluronan-binding proteins in tumor cells, we decided to use recombinant adenovirus constructs. Several constructs have been made in the laboratory, two of which have been used successfully in this study. These are recombinant adenoviruses driving expression of soluble CD44 and soluble BEHAB, a soluble hyaluronan-binding fragment derived from the proteoglycan, brevican (10). The adenoviruses were produced by routine methods (11) in which cDNA for each protein was cloned into an appropriate vector, then co-transfected with adenovirus into 293 cells which allow replication of the attenuated virus. After homologous recombination, the plaques were harvested and the virus purified and amplified. After determining successful expression of protein on infection of 293 cells, the viruses were used to infect C6 rat glioma cells. In both cases the protein (soluble CD44 or BEHAB) was expressed at high levels and secreted into the medium after infection with the respective adenovirus. A recombinant adenovirus expressing 1 3-galactosidase was used as a control.
B(iii). Perturbation of hyaluronan interactions inhibits anchorage-independent growth and invasiveness of tumor cells. We reported above that over-expression of soluble CD44 in TA3/St murine mammary carcinoma cells inhibits anchorage-independent growth in soft agar whereas over-expression of mutated CD44 that does not bind hyaluronan has no effect. The most likely interpretation of these results is that soluble CD44 acts by displacing endogenous hyaluronan from cell surface binding proteins. To substantiate this conclusion we have now studied the effect of treatment with hyaluronan oligomers on growth in soft agar. Hyaluronan oligomers would be expected to compete for endogenous polymeric hyaluronan binding but, in contrast to polymeric hyaluronan, would not bind multivalently (1), a property that has been shown to be important in hyaluronan signaling (2,3).
First we examined the effect of oligomers in routine monolayer culture of TA3/St murine mammary carcinoma cells and of C6 rat glioma cells. Growth under these conditions was unaffected by the oligomers. However, in soft agar the oligomers (100 [tg/ml) cause 50-70% inhibition of colony formation by these two cell types.
We have begun to examine the effect of: a. over-expression of soluble CD44 or BEHAB via infection with the respective adenoviruses (from B(ii) above), and b. treatment with hyaluronan oligomers, on tumor cell invasiveness, concentrating initially on glioma cells because of the importance of their invasive properties in malignancy. We have used three cell lines: rat C6, human A172 and human U87 glioma; these lines actively invade Matrigel, a widely used model for measuring invasiveness (12). Inclusion of hyaluronan oligomers (100ýtg/ml) in the Matrigel causes 70-90 % inhibition of invasion by the three cell types. Over-expression of soluble CD44 or BEHAB in C6 glioma cells causes 50-60% inhibition of invasion. 
CONCLUSIONS:
The results of these studies provide strong evidence for the direct involvement of hyaluronantumor cell interactions in the regulation of tumor growth and invasion. Consequently, perturbation of the pathways whereby hyaluronan influences tumor cell behavior may provide new avenues for therapeutic intervention in human patients. In a past study, we showed that hyaluronan accumuHyaluronan accumulates in ascites during intraperilates in the ascites, and at initial sites of attachment and toneal proliferation of TA3/St murine mammary carinvasion of tumor cells at the mesothelial surface of the cinoma cells and at sites of their invasion of the periperitoneal wall, after introduction of murine ovarian tumor toneal wall. To determine whether hyaluronan is cells or mammary carcinoma cells into the peritoneal functionally involved in these events, ascites tumor cavity of syngeneic mice.' Several types of malignant formation was compared in mice injected intraperisolid tumors contain elevated levels of hyaluronan, a toneally with stable transfectants of TA3/St cells that ubiquitous glycosaminoglycan that contributes both to overexpress solubleCD44, a hyaluronan-bindingprothe structure of extracellular matrix and to cell-matrix oeinvere sus soluble injcte4, a t h uroan-binding pro interactions that influence cell behavior. 5 ' 6 The enrichtein, versus in mice injected with transfectants exmn fhauoa ntmr a eutfo nrae pressing mutated soluble CD44 that does not bind ment of hyaluronan in tumors can result from increased hyaluronan. The soluble CD44 transfectants tempoproduction by tumor cells themselvesur or from interacrariy gew t a edued ate ithn te peitoeal tions between tumor cells and surrounding stromal cells rarily grew at a reduced rate within the peritoneal that induce increased production by the latter.
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9 '-High cavity, then went into G 1 arrest and were subselevels of hyaluronan correlate with tumor spread and with poor survival rates in human patients with a variety of transfectants overexpressing mutant soluble CD44 tumor types, 12 -" 5 and experimental evidence in animal that does not bind hyaluronan exhibited similar asmodels directly implicates hyaluronan in solid tumor procites accumulation, growth rates, and cell-cycle progression. 16 -20 In the present study our objective was to files in vivo to wild-type and vector-transfected TA3/St determine whether hyaluronan also contributes to ascites cells, all of which continued to grow until the tumors growth and tumor cell invasion of the peritoneal wall. became fatal. The soluble CD44-transfected TA3/St
We have shown that stable transfection of TA3/St mucells also failed to attach to and form tumors in the rine mammary carcinoma cells with cDNA encoding solperitoneal wall. When grown in vitro in soft agar, the uble CD44 prevents formation of metastatic nodules in soluble CD44 transfectants exhibited a dramatic rethe lung after introduction of the TA3/St cells into the duction in colony formation compared to wild-type, vasculature. 7 In that study, soluble CD44 presumably vector-transfected, and mutant soluble CD44-transacted as a competitive inhibitor of crucial hyaluronanfected TA3/St cells. Thus, perturbation of hyaluronan protein interactions because transfection with mutant solinteractions by soluble CD44 has a direct effect on the uble CD44 that does not bind hyaluronan had no effect growth characteristics of these tumor cells, leading to inhibition of anchorage-independent growth in vitro on invasion and metastasis. This supposition was con-
Tumorigenicity Assay
firmed by experiments showing that soluble CD44 transfection prevents hyaluronan-mediated clustering of en-TA3/St cells in log phase growth were trypsinized, dogenous membrane CD44 that is in turn required for washed with DMEM containing 10% FBS, and resusbinding of gelatinase B (MMP-9) to the tumor cell surface pended in Hanks' balanced salt solution (HBSS; Life and for invasiveness. 2 1 In the present study, we show Technologies, Inc.) for counting. Suspensions of TA3/St that stable transfection of TA3/St cells with soluble CD44 cell lines were injected, using a 25-gauge needle, into the not only inhibits tumor invasion but also prevents tumor peritoneal cavities of 4-to 6-week-old female A/Jax mice cell proliferation in ascites and that this inhibition is be-(The Jackson Laboratory, Bar Harbor, ME) at 1 x 106
cause of a direct effect on growth characteristics of the cells/200 A 1 HBSS each, and allowed to grow in vivo for a tumor cells rather than, or in addition to, an indirect effect period of 7 to 19 days. For each cell line and time point, on other events in vivo. These changes in tumor cell six mice were given injections. Mice were observed daily growth characteristics depend on hyaluronan interacfor signs of ascites tumor development and monitored tions because mutated soluble CD44 that does not bind twice daily after the tumor symptoms appeared: abdomhyaluronan does not cause these changes.
inal bloating, decreased movement, loss of grooming behavior, and hunched posture. If mice were not expected to survive overnight they were sacrificed before 24 G418-resistant colonies were seto 15 days. At each of five different time points (2, 5, 7, 10, lected and seven clones were chosen for further study: two and 15 days), groups of six mice were sacrificed and transfectants containing v6-vlO (v6-vlOa and v6-vl0b), one cells were harvested from the peritoneal cavities with two containing v8-vlO, two containing the v6-vlO mutant (v6-6-ml intraperitoneal lavages of calcium-and magnesiumvlO R43A), and two mock transfectants containing vector free PBS (PBS-; Life Technologies, Inc.). Harvested cells only. The transfectants were analyzed by reverse transcripwere then washed three times with PBS-, using lowtase-polymerase chain reaction, fluorescence-activated cell speed centrifugation with each wash to remove any red sorting, and Western blotting as described previously 17 to blood cells that were withdrawn along with tumor cells confirm that each clone expresses the appropriate CD44 from the peritoneal cavity; the tumor cells formed a pellet protein. All transfectants and wild-type cells produced simwhile the red blood cells remained in the supernatant ilar amounts of surface-associated, standard, and variant during these centrifugations. The washed cells were CD44 isoforms. However the soluble CD44 transfectants, counted in a Coulter Counter (Coulter Electronics, Hiincluding the mutant soluble CD44 transfectants, also proaleah, FL) by diluting aliquots of cells resuspended in duced soluble, secreted CD44. 
Materials and Methods

Cell-Cycle Analyses Results
Transfected and wild-type TA3/St cells were grown intra-
Transfection of TA3/St Cells with Soluble
peritoneally for 7 days, harvested, and washed as de-
CD44 cDNA
scribed in the previous section. They were then resuspended in 70% EtCH and kept at -20°C until all samples Stable transfectants overexpressing the naturally occurhad been collected for cell-cycle analysis. After removal ring soluble CD44 isoforms, v6-v10 and v8-v10, 2 3 the from the freezer, the cells were washed twice with PBS-, mutant isoform, v6-vl0 R43A, 24 or vector alone were resuspended in PBS-containing 0.1 mmol/L EDTA, pH selected and analyzed for CD44 production and secre-7.4, 50 mg/ml propidium iodide, 50 mg/ml RNase A tion as described in Materials and Methods. All cell lines (Boehringer Mannheim, Indianapolis, IN), and 1% Triton produced similar amounts of membrane-bound CD44. X-100, and incubated overnight at 40C. Cell samples Only the soluble CD44 transfectants, including the muwere then analyzed by fluorescence-activated cell sorttant soluble CD44 transfectants, produced secreted ing in a FACScan (Becton Dickinson, Mountain View, CA).
CD44; clones were selected that produced similar Transfected and wild-type cells were cultured in vitro in amounts of soluble CD44.1 7 Binding of hyaluronan to the DMEM plus 10% FBS, then harvested during log phase of soluble CD44 transfectants and their adhesion to a hyagrowth, and analyzed in the same way as above.
luronan substratum were shown previously to be reduced compared to wild-type TA3/St cells and vector controls. Soft agar assays were performed in 60-mm dishes contransfectants, only one of each control transfectant was taining 2 ml of 1.2% agarose diluted with 2x DMEM examined in detail. Three soluble CD44 transfectant containing 20% FBS to yield a final agarose concentraclones, two expressing v6-vl0 and one expressing v8-tion of 0.6%. Cells were harvested from monolayer culture v10, were examined in detail. Table 1 summarizes the tionof .6% Cels erehareste frm mnolyerculure results of one such experiment in which ascites accumuin log growth phase by trypsinization, washing, and relton or grwh andetumor invasioer cmpr suspnsin i DME cotaiing 0% BS or cuntng. lation, tumor growth, and tumor invasion were compared suspension in DMEM containing 10% FBS for counting.
in the above manner in groups of six animals that were The cells were then suspended in 0.33% agarose in injected with either wild-type TA3/St cells, one of the DMEM containing 10% FBS and plated at 5000 cells/well vector transfectants, one of the mutant soluble CD44 on top of the 0.6% agarose base. After each agarose transfectants, or the two v6-vl0 soluble CD44 transfeclayer was allowed to solidify (10 minutes at 25oC), three tans. Identia re to those sow nble 1 for the additional 1-ml volumes of 0.33% agarose were layered two v6-vl0 transfectants were obtained for the v8-vl0 on top of the cells. Each cell line was plated in triplicate soluble CD44 transfectant in other similar experiments. and grown at 37 0 C for 28 days. Total numbers of colonies The results of these experiments are discussed below. per well containing >30 cells or >200 cells per colony
The mice injected with wild-type, vector-transfected, or were counted separately using a microscope grid. The mutant soluble CD44 (v6-vl0 R43A)-transfected cells accutwo classes of colony size were assessed by counting mulated ascites fluid and exhibited abdominal bloating, cells in numerous colonies under the microscope and symptomatic of ascites tumor development. Mice injected correlating these numbers with colony size. The two with either of the two v6-vl0 soluble CD44 transfectants or classes could be distinguished readily because the great with the v8-vl0 transfectant did not accumulate ascites fluid majority of colonies were found to contain between 30 or exhibit abdominal bloating. At 7 days or at 14 to 19 days and 100 cells; the large colonies (>200 cells) were very after injection of cells, the mice were sacrificed and their easily distinguished from the majority of colonies (30 to peritoneal walls were fixed and stained. At seven days, 100 cells) and there were virtually no colonies with <30 tumor cells had attached to regions of the peritoneal wall in cells.
wild-type, vector-transfected, or mutant soluble CD44 (v6- Soluble CD44 v6-vlOa 0/6 12/6 0/6 Soluble CD44 v6-vl~b 0/6 2•T/6 0/6 *Animals were examined for attachment to the peritoneal wall and mesentery at 7 days after injection (see Figure 1 ). tAnimals were examined for growth and invasion in the mesentery and peritoneal wall between 14 and 19 days after injection (see Figure 2 ). *Animals were examined for accumulation of ascites between 14 and 19 days after injection.
5
The soluble CD44 v8-vlO transfectant was not analyzed in this particular experiment but in other similar experiments it behaved in an identical fashion to that shown here for the v6-vlO transfectants.
'ULimited, focal regions of tumor cell attachment resulting in small accumulations of noninvading cells.
vl0 R43A)-transfected controls ( Figure 1A ). However, no cases (in all other situations at least six animals were tumor cells were observed attached to the peritoneal walls analyzed at each of the five time points). For the first 5 to of mice injected with the v6-v10 or the v8-v10 soluble CD44 7 days, the soluble CD44 transfectants grew significantly, transfectants ( Figure 1B ). Mice injected with wild-type, vecbut at a diminished rate compared to the controls. Subtor-transfected, or mutant soluble CD44-transfected cells sequently, between 10 and 15 days postinjection, their exhibited widespread tumorigenesis and invasion of the numbers became reduced to baseline (Figure 3 ). This mesothelium and muscle layers of the peritoneal walls by 14 rise and fall in number of cells is particularly evident for to 19 days (Figure 2 ; A, C, and D). In contrast, mice injected the transfectant overexpressing the v8-vlO soluble CD44 with v6-v10 or v8-vlO soluble CD44-transfected cells isoform, where the ascites cell number rose to -14 x 10' showed little or no tumor cell attachment to the mesothelium at day 7 after injection but fell back to baseline by 15 and no invasion of the peritoneal wall ( Figure 2B ). days ( Figure 3) . None of the animals carrying the soluble Because transfection with soluble CD44 cDNA elimi-CD44 transfectants accumulated ascites and most surnated ascites accumulation and invasion of the peritoneal vived indefinitely without any signs of tumor formation in wall, we directly analyzed growth of the injected cells to the peritoneal wall. A small number of these animals determine their fate in vivo. To facilitate high cell recovery slowly developed solid tumors outside the peritoneum from the peritoneal cavity, a larger number of cells, ie, near the site of tumor cell injection, presumably arising 2 x 10 e, was injected into the abdomen of each host from cells that leaked from the peritoneum during injecmouse than in the experiments above. The cells were tion or healing. recovered by intraperitoneal saline lavage at 2, 5, 7, 10, and 15 days postinjection and counted (Figure 3 ). Vector-transfected and soluble CD44 R43A-transfected cells Soluble CD44-Transfected TA3/St Mammary grew rapidly for the first 10 days after injection; however,
Carcinoma Cells Enter G 1 Arrest in Ascites
most of these animals then became terminally ill and were sacrificed before day 15. Consequently only one to two Wild-type and transfected TA3/St cells were harvested at animals remained for analysis at the 15-day point in these 7-days postinjection from the peritoneal cavity of mice Table 1 ), or v8-vlO. Scale bar, 50 .tm. Table 1 ), and v8-vI0 transfectants. Scale bar, 100 ltm.
injected with 2 x 106 cells. These cells were then ana- 
60-
46-y-
R43A
CD44 R43A-transfected cells demonstrated a cell-cycle profile typical of an asynchronously cycling cell popular tion ( Figure 4 ; Table 2 ). The proportion of cells in G/G1 0I for each population was calculated to be approximately 30 to 40% for the various control populations compared o 20 to 75 to 85% for the soluble CD44 transfectants (Table 2) .
For comparison, the various cell lines were grown in from -30 to 50% cells in Go/G, ( Table 2) .
Days in vivo
In a further attempt to understand the fate of the solu- vivo for 5 days, checked that they had gone into G, (v6-vl0a, v6-vl0b, v8-v10) various cell lines. vector-transfected control. Quantitative data are given in Table 2 . A similar cell-cycle pattern to that of the vector-transfected cells (B) was obtained with wild-type and mutant soluble CD44-transfected cells; the cell-cycle patterns consequence of another event in vivo. Thus we sought seen with all three soluble CD44 transfectants, v6-vlOa, v6-vl0b, and v8-vlO, additional evidence to discriminate between these two were similar to that shown in A (see Table 2 ). possible explanations.
First, proliferation of the soluble CD44 transfectants cites, the soluble CD44 transfectants irreversibly entered and control cells was compared in monolayer culture in G, arrest, subsequently died, and were cleared from the tissue culture wells. Each cell line grew at approximately peritoneum.
the same rate during a 5-day period ( Figure 5 ) and exhibited similar cell-cycle profiles (Table 2) . ,CD44-Transfected
TA3/St Mammary
We then examined anchorage-independent growth of the various cell lines in soft agar. Dramatic differences in colonies than the soluble CD44 transfectants, and the characteristics within the ascites and to inhibition of pericolonies formed by the control cells were larger than toneal wall implantation. Previous studies have also imthosefew colonies formed by the soluble CD44 transfecplicated interactions between tumor cell surface CD44 tants (Table 3) .
Carcinoma Cells Have Lost the Capacity for
and mesothelial cell-derived hyaluronan in tumor cell attachment to the peritoneal wall. 4 surface hyaluronan interactions by soluble CD44 gives A particularly striking finding of this study was the rise to direct inhibitory effects on tumor cell growth. We failure of TA3/St transfectants overexpressing soluble have shown that the soluble CD44 transfectants, but not CD44 to form ascites tumors. For each of the three soluthe mutant soluble CD44 transfectant, have lost their ble CD44 transfectants tested, growth took place for ability to exhibit anchorage-independent growth in soft several days in the peritoneum subsequent to inoculaagar, a commonly used indicator of the transformed state tion. However, the rate of growth of the soluble CD44 of cells.
3 ' 3 1 Thus it would seem that endogenous hyalutransfectants was slower than for controls and the former ronan produced by the tumor cells themselves serves an cells went into G, arrest; the control cells, however, conimportant function in anchorage-independent growth. tinued to increase in number to a point that became fatal This conclusion is supported by recent experiments for the host animals. Growth of the soluble CD44-transshowing that increased expression of hyaluronan, driven fected cells not only ceased but the numbers of cells in by transfection with cDNA for hyaluronan synthase, leads the ascites decreased back to an insignificant level. Deto acquisition of the ability to grow in soft agar. 19 Howpending on the particular transfectant, 3 to 14 million ever, it is unlikely that the effect of overexpression of cells per mouse were lost from the peritoneum between 5 soluble CD44 is because of changes in hyaluronan synand 15 days postinoculation, implying that the soluble thesis because none of the parent or transfected cell CD44 transfectants not only went into G 1 arrest but also lines produce large amounts of hyaluronan. Rather, it is subsequently died and were cleared from the peritoneal more likely that soluble CD44 disrupts the organization of cavity. In a parallel study, we have compared the ability endogenous pericellular hyaluronan with respect to its of the soluble CD44-transfected and vector-transfected interactions with CD44 or other hyaluronan-binding pro-TA3/St cells studied herein to form metastases in the lung teins that are important for the transformed behavior of after intravenous injection. 1 7 In that study, overexpresthe parent and control cells, eg, CD44-mediated docking sion of soluble CD44 was shown to induce apoptosis of MMP-9 (see below). Also, in vivo, both parent and subsequent to entry of the cells into lung tissue, and soluble CD44 transfectants induce high hyaluronan levconsequently formation of metastatic nodules was draels in surrounding stromal tissue, 17 indicating that this is matically inhibited. In the current study it is also probable not the underlying difference in their behavior in vivo. that the soluble CD44 transfectants became apoptotic, Recent work from one of our laboratories 21 has demalthough we were unable to capture the cells for analysis onstrated binding of MMP-9 to CD44 at the surface of during the window of time between appearance of apo-TA3/St murine mammary carcinoma and MC human melptotic characteristics and clearance of the cells from the anoma cells. This binding of MMP-9 to CD44 is depenascites. TA3/St cells transfected with mutated soluble dent on hyaluronan-induced clustering of CD44 in the CD44 (R43A) behaved like vector-transfected controls plasma membrane. Overexpression of soluble CD44 dis- (Figure 3 ), indicating that an hyaluronan-mediated interrupts clustering of endogenous membrane CD44 and action is involved in these effects of soluble CD44 on thus inhibits complex formation with MMP-9. Complex growth.
formation between CD44 and MMP-9 has also been obInterestingly, the cell number reached in the peritoserved in other mammary carcinoma cell lines. 32 Docking neum for the soluble CD44 transfectants, 5 to 7 days after of MMP-9 at the surface of TA3/St cells promotes its inoculation, was sufficient for widespread attachment to activity, possibly via protection from tissue inhibitors of the peritoneal wall to occur in the case of the controls.
MMPs, which in turn leads to enhanced tumor invasion However, no attachment of soluble CD44 transfectants and angiogenesis. 21 ,' 33 Cell surface-bound MMP-9 acts, was detected. This observation suggests that perturbed at least in part, by activating latent transforming growth hyaluronan-CD44 interactions lead both to altered growth factor-P31 (TGF-/3) which then stimulates new blood ves- 
